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Abstract
Objective:  Secretory  phospholipase  A2  (sPLA2)  enzyme  activity  is  a  potential  inﬂammatory
biomarker  for  cardiovascular  disease.  We  examined  the  tracking,  or  persistence,  of  sPLA2
enzyme activity  levels  from  childhood  to  adulthood,  and  identify  potentially  modiﬁable  factors
affecting  tracking.
Method:  Prospective  cohort  of  1735  children  (45%  females)  who  had  serum  sPLA2  enzyme  activ-
ity levels  and  other  cardiovascular  disease  risk  factors  measured  in  1980  that  were  followed-up
in 2001.
Results:  sPLA2  activity  tracked  from  childhood  to  adulthood  for  males  (r  =  0.39)  and  females
(r =  0.45).  Those  who  decreased  body  mass  index  relative  to  their  peers  were  more  likely  to
resolve elevated  childhood  sPLA2  levels  than  have  persistent  elevated  sPLA2  levels  in  childhood
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and  adulthood.  Those  who  consumed  less  fruit,  and  gained  more  body  mass  index  relative  to
their peers,  began  smoking  or  were  a  persistent  smoker  between  childhood  and  adulthood  were
more likely  to  develop  incident  elevated  sPLA2  levels  than  those  with  persistent  not  elevated
sPLA2 levels.
Conclusions:  Childhood  sPLA2  enzyme  activity  levels  associate  with  adult  sPLA2  levels  21  years
later. Healthful  changes  in  modiﬁable  risk  factors  that  occur  between  childhood  and  adulthood
might prevent  children  from  developing  elevated  sPLA2  levels  in  adulthood.
© 2018  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Pediatria.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Monitoramento  dos  níveis  de  atividade  da  enzima  fosfolipase  A2  secretória  da
infância  à  vida  adulta:  uma  coorte  de  21  anos
Resumo
Objetivo:  A  atividade  da  enzima  fosfolipase  A2  secretória  (sPLA2)  é  um  possível  biomarcador
inﬂamatório  de  doenc¸a  cardiovascular.  Examinamos  o  monitoramento,  ou  a  persistência,  dos
níveis de  atividade  da  enzima  sPLA2  da  infância  à  vida  adulta  e  identiﬁcamos  fatores  possivel-
mente modiﬁcáveis  que  afetam  o  monitoramento.
Método:  Coorte  prospectiva  de  1735  crianc¸as  (45%  do  sexo  feminino)  cujos  níveis  de  atividade
da enzima  sPLA2  no  soro  e  outros  fatores  de  risco  para  doenc¸a  cardiovascular  foram  medidos
em 1980  e  acompanhados  até  2011.
Resultados:  Atividade  da  enzima  sPLA2  monitorada  da  infância  à  vida  adulta  para  indivíduos
do sexo  masculino  (r  =  0,39)  e  sexo  feminino  (r  =  0,45).  Aqueles  que  diminuíram  seus  índices  de
massa corporal  com  relac¸ão  a  seus  pares  foram  mais  propensos  a  reduc¸ão  dos  níveis  elevados
de sPLA2  na  infância  que  manter  níveis  persistentemente  elevados  de  sPLA2  na  infância  e  vida
adulta. Aqueles  que  consumiram  menos  frutas  e  ganharam  mais  índice  de  massa  corporal  com
relac¸ão a  seus  pares,  que  comec¸aram  a  fumar  ou  foram  fumantes  persistentes  entre  a  infância
e vida  adulta  foram  mais  propensos  a  desenvolver  níveis  de  sPLA2  elevados  que  aqueles  com
níveis de  sPLA2  não  elevados  persistentes.
Conclusões:  Os  níveis  de  atividade  da  enzima  sPLA2  na  infância  estão  associados  aos  níveis  de
sPLA2 na  vida  adulta,  21  anos  mais  tarde.  As  mudanc¸as  saudáveis  nos  fatores  de  risco  modi-
ﬁcáveis que  ocorrem  entre  a  infância  e  a  vida  adulta  podem  evitar  que  as  crianc¸as  desenvolvam
níveis elevados  de  sPLA2  na  vida  adulta.
© 2018  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Pediatria.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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nﬂammatory  biomarkers  have  been  observed  in  all  stages  of
therosclerosis  development.1 Research  into  secretory  phos-
holipase  A2  (sPLA2)  enzyme  activity  has  gained  interest
ver  other  inﬂammatory  biomarkers  owing  to  its  increased
peciﬁcity  to  the  vasculature.2
sPLA2  belongs  to  a  superfamily  of  enzymes  known  as
he  phospholipase  A2s.  These  enzymes  are  responsible  for
atalysing  the  hydrolysis  of  fatty  acid  from  the  sn-2  position
f  membrane  phospholipids,  the  release  of  polyunsaturated
atty  acids,  and  host  defence  against  bacterial  infection.3
elease  of  sPLA2  promotes  production  of  many  eicosanoids
nd  bioactive  lipid  mediators.4 The  effect  of  sPLA2  on
ipoproteins  releases  several  lipid  mediators  at  the  place
f  lipoprotein  retention  within  the  wall  of  the  artery,  trig-
ering  local  inﬂammatory  cellular  responses.5 sPLA2  also
as  direct  action  on  low-density  lipoprotein  (LDL)  parti-
les,  inducing  them  to  have  a  more  atherogenic  effect.5
l
a
p
these  sPLA2-induced  changes  are  thought  to  contribute
o  atherosclerosis  development,6,7 sparking  interest  as  a
otential  target  for  intervention.  Although  early  phase  clin-
cal  trials  have  supported  the  efﬁcacy  of  sPLA2  inhibition
sing  pharmacological  intervention,8--10 the  only  phase  III
rial  conducted  revealed  contrary  results,11 and  results  from
endelian  randomisation  studies  have  been  equivocal  of  a
ausal  role  for  sPLA2  enzyme  activity  in  cardiovascular  dis-
ase  (CVD)  outcomes.12,13
Vessel  changes  favouring  atherosclerosis  begin  in
hildhood14 and  traditional  CVD  risk  factors  (lipoproteins,
lood  pressure,  adiposity)  track,  or  persist,  from  childhood
o  adulthood.15 However,  no  studies  have  examined  if  sPLA2
nzyme  activity  levels  track  from  childhood  to  adulthood.
sing  data  from  the  21-year  follow  up  of  the  Cardiovascu-
ar  Risk  in  Young  Finns  Study,  we  examined  if  sPLA2  enzyme
ctivity  levels  track  from  childhood  to  adulthood,  and  the
otentially  modiﬁable  lifestyle-related  factors  that  affect
racking  over  this  period.
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Tracking  of  secretory  phospholipase  A2  levels  
Methods
Study  population
The  Cardiovascular  Risk  in  Young  Finns  Study  is  a  population-
based  prospective  follow-up  on  3596  Finnish  children  and
adolescents  aged  3--18  years  who  participated  at  base-
line  in  1980.  In  2001,  2283  of  the  baseline  participants
attended  clinics,  aged  24--39  years.  Measurements  of  serum
sPLA2  were  performed  on  those  with  available  samples  from
both  1980  and  2001  (n  =  2245).  We  excluded  participants
who  had  a  condition  that  may  predispose  them  to  altered
sPLA2  levels:  participants  with  chronic  rheumatic  dis-
ease  (n  =  34;  sPLA2  activity  1.80  (1.29--2.22)  nmol/min/ml
in  2001);  females  who  reported  they  were  pregnant
(n  =  59;  sPLA2  activity  1.67  (1.33--2.08)  nmol/min/ml  in
2001);  participants  who  reported  having  an  infection  with
fever  in  the  last  2  weeks  (n  =  104;  sPLA2  activity  1.65
(1.32--2.08)  nmol/min/ml  in  2001);  females  who  reported
current  use  of  oral  contraceptives  (n  =  288;  sPLA2  activity
1.78  (1.39--2.28)  nmol/min/ml  in  2001;  n  =  25;  sPLA2  activ-
ity  0.52  (0.41--0.97)  nmol/min/ml  in  1980).  After  exclusions,
data  on  1735  participants  were  left  for  our  primary  analy-
ses.  The  study  was  conducted  according  to  the  Declaration
of  Helsinki,  and  local  ethics  committees  approved  the  study
protocols.  Written  informed  consent  was  obtained  from  all
participants  in  2001,  and  their  parents  in  1980.
Clinical  measurements  and  risk  factors
At  both  time-points,  height  was  measured  with  a Seca
anthropometer  and  weight  was  measured  with  Seca  scales
(Vogel  Halke,  Hamburg,  Germany).  Body  mass  index  (BMI,
kg/m2)  was  calculated.  Self-report  questionnaires  adminis-
tered  at  baseline  and  follow-up  collected  data  on  smoking,
dietary  habits,  and  physical  activity.16 Information  on  smok-
ing  habits  was  only  collected  amongst  participants  aged
12--18  years  at  baseline.  Participants  who  smoked  at  least
weekly  at  baseline  or  daily  at  follow-up  were  considered
smokers.  Fruit  and  vegetable  consumption  was  reported
based  on  six  options  (1  =  daily,  2  =  almost  every  day,  3  =  a  cou-
ple  of  times  per  week,  4  =  about  once  a  week,  5  =  a  couple  of
times  per  month,  6  =  less  than  a  couple  of  times  per  month),
which  was  converted  into  times  of  consumption  per  week
(1,  >9.5;  2,  >6.3;  3,  >3;  4,  >1.2;  5,  >0.3;  6,  >0.1).17 Physical
activity  index  (range  from  5  (low)  to  15  (high)),  was  deter-
mined  by  participant’s  self-report  of  duration,  intensity,
and  frequency  of  physical  activity.18 Socioeconomic  posi-
tion  (SEP)  was  based  on  highest  level  of  parental  occupation
at  baseline  (manual,  lower-grade  non-manual,  higher-grade
non-manual)  and  participant  occupation  at  follow-up.19
Serum  sPLA2  enzyme  activity  measurements
In  1980  and  2001,  blood  samples  were  taken  from  the  ante-
cubital  vein  after  participants  conﬁrmed  they  had  fasted
overnight.  Serum  sPLA2  enzyme  activity  was  measured
in  2006  from  1980  blood  samples  stored  at  −20 ◦C,  and
2001  samples  stored  at  −80 ◦C.20 Measurement  of  sPLA2
enzyme  activity  includes  several  groups  of  sPLA2  (IIA,  V,
p
s
a PRESS
3
)21 expressed  in  atherosclerotic  lesions  from  human  and
nimal  models.22 Hydrolysis  of  substrate  without  plasma
as  used  as  the  negative  control  and  deduced  from  sPLA2
ctivity.  Samples  were  tested  in  duplicate.  Intra-  and  inter-
ssay  coefﬁcients  of  variation  were  <10%  and  the  minimum
etectable  level  of  sPLA2  activity  was  0.10  nmol/min/ml.
tatistical  analyses
ll  analyses  were  performed  using  STATA  13.1  (StataCorp,
ollege  Station,  TX,  USA).
emographics
aseline  and  follow-up  characteristics  are  displayed  for
ale  and  female  participants.  Continuous  variables  are  dis-
layed  as  mean  (standard  deviation)  for  normally  distributed
ariables  and  median  (25--75th  percentiles)  for  variables
ith  a  non-normal  distribution.  Categorical  variables  are
isplayed  as  N  (percent).  We  also  plot  age  on  mean  sPLA2
nzyme  activity  levels  by  sex.
racking  of  sPLA2  levels  from  childhood  to
dulthood
racking  was  estimated  by  two  approaches  used  in  previ-
us  tracking  studies23,24:  (1)  rank  correlations  by  applying
earson’s  correlation  to  the  rank  of  baseline  and  follow-up
PLA2  measurements;  and  (2)  the  proportion  of  participants
emaining  in  the  upper  quarter  of  age-  and  sex-speciﬁc
PLA2  distributions  at  both  time-points.  We  report  partial
orrelations  adjusted  for  age  when  ages  are  combined,
r  adjusted  age  and  sex  when  data  for  age  and  sex  are
ombined.  sPLA2  measurements  at  both  time-points  were
anked  prior  to  correlation  analyses  owing  to  a  right-skewed
istribution.  We  performed  Pearson’s  correlation  on  the
PLA2  ranks,  as  STATA  does  not  have  a  function  to  perform
artial  Spearman’s  correlations.
actors  affecting  sPLA2  levels  from  child  to
dulthood
articipants  were  divided  into  four  tracking  groups  based  on
heir  sPLA2  enzyme  activity  status  from  childhood  to  adult-
ood.  Participants  who  remained  in  the  upper  quarter  of
ge-  and  sex-speciﬁc  sPLA2  distributions  at  both  time-points
ere  classiﬁed  as  persistent  elevated;  those  who  were  in
he  upper  quarter  in  childhood  but  not  at  follow-up  were
lassiﬁed  as  resolution;  those  who  were  not  in  the  upper
uarter  in  childhood  but  were  in  adulthood  were  classiﬁed
s  incident;  and  those  who  did  not  have  sPLA2  levels  in
he  upper  quarter  at  both  childhood  and  adulthood  were
lassiﬁed  as  persistent  not  elevated  (Supplemental  Fig.  1).
his  approach  has  been  adopted  in  other  studies  examining
actors  that  inﬂuence  tracking  of  lipids  and  blood  pressure
etween  childhood  and  adulthood.23,24Changes  (adult  minus  child)  in  continuous  variables  (BMI,
hysical  activity  index,  fruit  consumption,  vegetable  con-
umption)  were  analysed  using  age-  and  sex-speciﬁc  z-scores
t  each  time-point.  As  an  indicator  of  change  or  stability
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n  SEP,  we  created  a  categorical  social  mobility  variable25
hat  considered  the  highest  level  of  parental  (mother  or
ather)  occupation  at  baseline  and  participant  occupation  at
ollow-up.19 This  variable  has  the  following  categories:  per-
istently  low  (low  at  baseline  and  follow-up),  persistently
edium  (medium  at  baseline  and  follow-up),  persistently
igh  (high  at  baseline  and  follow-up),  upwardly  mobile  (mov-
ng  from  medium  at  baseline  to  high  at  follow-up,  or  low  at
aseline  to  medium  or  high  at  follow-up),  and  downwardly
obile  (moving  medium  at  baseline  to  low  at  follow-up,
r  from  high  at  baseline  to  medium  or  low  at  follow-up).
articipants  were  categorised  into  one  of  four  categories
ased  on  their  smoking  status  at  both  time-points:  not
moking  at  either  time-point,  stopped  smoking  (smoking  at
aseline,  not  at  follow-up),  began  smoking  (did  not  smoke
t  baseline,  smoked  at  follow-up),  and  smoker  at  both
ime-points.
Using  logistic  regression,  we  compared  changes  in  the
ifestyle-related  variables  of  BMI,  physical  activity  index,
a
a
n
f
Table  1  Characteristics  of  up  to  1735  participants  in  the  Cardiov
lipase (sPLA2)  enzyme  activity  measurements  in  childhood  (1980)  
Characteristic  Male
Na Sta
Childhood
Age,  y  962  10
sPLA2 activity,  nmol/mL/min  962  0.
Height, cm  957  144
Weight, kg  957  40
Body mass  index,  kg/m2 956  18
Physical activity  indexb 643  9
Fruit consumption,  serves/wk  950  6
Vegetable consumption,  serves/wk  949  6
Currently smoking  ≥  once/weekc 466  
Parental occupational  status  943  
Manual 3
Lower non-manual  3
Upper non-manual  1
Adulthood
Age, y  959  31
sPLA2 activity,  nmol/mL/min  962  1.
Height, cm  956  179
Weight, kg  957  83
Body mass  index,  kg/m2 956  25
Physical activity  index  899  9
Fruit consumption,  serves/wk  934  5
Vegetable consumption,  serves/wk  930  4
Currently smoking  daily  932  2
Participant’s  occupational  status  814  
Manual 3
Lower non-manual  2
Upper non-manual 2
Statistics are mean (SD) or median (25th, 75th percentiles) for continu
a Changing Ns are the result of missing data for some variables.
b Only participants aged 9 years or older at baseline had physical act
c Only participants aged 12 years or older at baseline had smoking da PRESS
Chung  O  et  al.
ruit  consumption,  vegetable  consumption,  smoking  status,
nd  social  mobility  between  persistent  elevated  (reference)
nd  resolution  sPLA2  tracking  groups  and  between  persistent
ot  elevated  (reference)  and  incident  sPLA2  tracking  groups.
s  no  signiﬁcant  sex  interactions  were  observed,  the  data
re  not  stratiﬁed  by  sex.
esults
emographics
haracteristics  outlining  the  population  are  presented  in
able  1.  At  baseline  and  follow  up,  females  had  higher  sPLA2
nzyme  activity  levels  compared  with  males.  Fig.  1  dis-
lays  mean  sPLA2  enzyme  activity  levels  as  a  function  of
ge  at  both  time-points.  There  was  a  signiﬁcant  (negative)
ge  trend  for  boys  aged  3--18  years  (p  <  0.001).  There  were
o  clear  age  trends  in  girls,  or  in  adulthood  for  males  or
emales.
ascular  Risk  in  Young  Finns  Study  who  had  secretory  phospho-
and  adulthood  (2001).
s  Females
tistic  Na Statistic
.7  (5.0)  773  11.3  (4.8)
57  (0.37--0.84)  773  0.72  (0.48--1.02)
.6  (27.5)  773  143.7  (22.9)
.7  (20.0)  771  39.5  (16.1)
.0  (3.2)  771  18.1  (3.0)
.6  (1.9)  545  8.6  (1.6)
.7  (2.9)  767  6.9  (2.8)
.1  (2.9)  767  6.3  (2.8)
71  (15.2)  431  44  (10.2)
756
96  (42.0)  321  (42.5)
78  (40.1)  311  (41.1)
69  (17.9)  124  (16.4)
.7  (5.0)  772  32.3  (4.8)
37  (1.10--1.69)  773  1.61  (1.30--2.00)
.4  (6.5)  768  165.9  (5.9)
.0  (14.7)  768  67.9  (14.0)
.8  (4.1)  768  24.7  (4.9)
.9  (2.5)  716  9.9  (2.2)
.0  (3.1)  748  6.3  (3.0)
.9  (3.1)  741  6.1  (3.1)
81  (30.2)  757  139  (18.4)
675
53  (43.4)  163  (24.2)
22  (27.3)  389  (57.6)
39  (29.4)  123  (18.2)
ous variables or N (percent) for categorical variables.
ivity data collected.
ta collected.
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Figure  1  Estimated  means  and  95%  conﬁdence  intervals  for
secretory  phospholipase  (sPLA2)  enzyme  activity  levels  as  a
function  of  age  in  males  and  females.  Data  for  males  indicated
by black  circles;  data  for  females  indicated  by  white  circles.
Sample  sizes  for  each  age  and  sex  sub-group  were:  3-years/24-
years  (males,  n  =  150;  females,  n  =  82);  6-years/27-years  (males,
n =  137;  females,  n  =  114);  9-years/30-years  (males,  n  =  175;
females,  n  =  129);  12-years/33-years  (males,  n  =  165;  females,
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tn =  158);  15-years/36-years  (males,  n  =  175;  females,  n  =  156);
18-years/39-years  (males,  n  =  160;  females,  n  =  134).
Tracking  of  sPLA2  levels  from  youth  to  adulthood
Correlations  between  childhood  and  adult  sPLA2  activity
levels  (range,  males:  r  =  0.31--0.44;  females:  r  =  0.25--0.58)
were  observed  across  both  sexes  and  for  all  age  groups  (Sup-
plemental  Table  1).  42.3%  of  males  and  35.8%  of  females  who
were  in  the  highest  quarter  for  sPLA2  levels  in  childhood
remained  in  the  highest  quarter  in  adulthood  (Supplemen-
tal  Table  2).  The  proportion  of  participants  in  the  lower
quarter  at  both  time-points  was  41.2%  for  males  and  48.4%
for  females.  For  the  entire  cohort,  the  rank-correlation  for
tracking  of  sPLA2  enzyme  activity  was  r  =  0.41,  upper  quarter
tracking  was  39.4%,  and  lower  quarter  tracking  was  44.3%.
Fig.  2 displays  rank  correlations  and  proportion  remaining
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Figure  2  Pearson’s  correlation  coefﬁcients  by  baseline  age
for tracking  of  secretory  phospholipase  (sPLA2)  enzyme  activ-
ity between  childhood  and  adulthood  (upper  ﬁgure  portion);
and percent  remaining  in  the  extreme  quarter  of  the  sample
distribution  for  sPLA2  enzyme  activity  between  childhood  and
adulthood  by  baseline  age  (lower  ﬁgure  portion).  Data  for  males
indicated  by  black  line  and  bars;  data  for  females  indicated  by
grey line  and  bars.
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5
n  the  upper  quarter  at  both  time-points  for  each  age-  and
ex-stratum.
actors  affecting  sPLA2  levels  from  youth  to
dulthood
able  2  shows  the  association  of  changes  in  different  lifestyle
actors  on  the  tracking  of  sPLA2  enzyme  activity  groups.
ompared  with  those  in  the  persistent  elevated  group,  the
esolution  group  had  decreased  their  BMI  relative  to  peers
ho  had  experienced  a relative  increase  in  BMI.
Comparing  incident  and  persistent  not  elevated  sPLA2
nzyme  activity  groups,  those  in  the  incident  group  tended
o  have  gained  more  BMI  and  decreased  fruit  consumption
ompared  with  those  in  the  persistent  not  elevated  group,
ho  had  maintained  stable  BMI  and  had  increased  fruit  con-
umption  relative  to  their  peers.  Those  in  the  incident  group
ere  also  more  likely  to  have  begun  smoking  since  child-
ood  (21.1%  vs.  15.3%),  or  were  a  smoker  at  both  time-points
11.9%  vs.  5.0%).
iscussion
PLA2  is  a  marker  of  vascular  inﬂammation  that  might  have  a
ole  in  the  pathogenesis  of  atherosclerosis.  Since  exposure
o  risk  factors  in  childhood  contributes  to  atherosclerosis
ater  in  life,  we  examined  the  ability  to  predict  adult  sPLA2
evels  from  measures  collected  in  childhood  (tracking).  We
howed  that  sPLA2  enzyme  activity  in  childhood  correlates
ith  levels  measured  21  years  later  in  adulthood  and  that
pproximately  40%  of  children  with  high  levels  maintain  this
evel  to  adulthood.  Furthermore,  our  ﬁndings  suggest  that
ealthy  improvements  in  the  modiﬁable  risk  factors  of  fruit
onsumption,  smoking  status,  and  BMI  have  the  potential
o  decrease  the  development  of  an  elevated  sPLA2  level  in
dulthood.
As no  previous  studies  have  examined  the  tracking  of
PLA2  levels  spanning  childhood  to  adulthood,  we  provide
omparison  with  tracking  of  other  CVD  risk  factors  reported
n  earlier  ﬁndings  from  the  Cardiovascular  Risk  in  Young  Finns
tudy  (Supplemental  Table  3).16 On  the  basis  of  rank  corre-
ations,  sPLA2  enzyme  activity  tracked  similarly  compared
ith  other  established  risk  factors  (lipoproteins,  BMI,  sys-
olic  blood  pressure).  Of  interest,  sPLA2  enzyme  activity
racked  more  strongly  than  high-sensitivity  C-reactive  pro-
ein  (hsCRP,  r  =  0.43  vs.  r  =  0.29),  an  inﬂammatory  biomarker
inked  to  atherosclerosis  and  CVD.6,16,20 Previously,  we  have
ound  child  lipoproteins,  blood  pressure,  and  BMI  to  predict
dult  carotid  intima-media  thickness  (cIMT),  an  established
reclinical  marker  of  atherosclerosis,  independent  of  adult
evels  of  the  same  risk  factors.26 However,  child  hsCRP  was
ot  associated  with  adult  cIMT.16 Should  a  causal  role  of
PLA2  in  preclinical  atherosclerosis  be  conﬁrmed,  and  if
PLA2  enzyme  activity  tracks  as  our  data  suggest,  future
tudies  could  examine  the  utility  of  child  sPLA2  enzyme
ctivity  levels  to  predict  adult  markers  of  atherosclerosis
ndependent  of  other  risk  factors.In  the  absence  of  support  from  clinical  trials  spanning
ultiple  decades,  our  data  also  suggest  positive  changes
ade  to  lifestyle-related  risk  factors  in  the  time  between
hildhood  and  adulthood  might  help  individuals  to  improve
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Table  2  Factors  affecting  tracking  of  secretory  phospholipase  A2  (sPLA2)  enzyme  activity  from  childhood  (1980)  to  adulthood
(2001) in  the  Cardiovascular  Risk  in  Young  Finns  Study.
Factor  sPLA2  trajectory  group
Persistent  elevated  Resolution  Incident  Persistent  not  elevated
N  Statistica N  Statistica N  Statistica N  Statistica
  Body  mass  index  z-score 168  0.17  (1.17) 258  −0.01  (0.92)c 218  0.14  (0.98) 1072  0.00  (0.95)b
  Physical  activity  z-score  107  0.15  (1.18)  164  0.04  (1.17)  150  −0.03  (1.21)  681  −0.05  (1.21)
 Fruit  consumption  z-score  167  −0.13  (1.25)  250  −0.01  (1.30)  214  −0.17  (1.21)  1034  0.07  (1.33)b
  Vegetable  consumption  z-score  166  0.08  (1.32)  250  0.17  (1.32)  213  −0.04  (1.22)  1023  0.01  (1.28)
Smoking status,  %
Not  smoking  at  either  time-point  58  69.9  84  63.6  67  61.5  402  73.9
Stopped smoking  4  4.8  10  7.6  6  5.5  32  5.9
Began smoking  13  15.7  26  19.7  23  21.1  83  15.3c
Smoker  at  both  time-points  8  9.6  12  9.1  13  11.9  27  5.0b
Social  mobility,  %
Persistently  low  27  18.9  46  21.0  36  19.6  172  18.9
Persistently  moderate  26  18.2  44  20.1  33  17.9  157  17.2
Persistently  high  10  7.0  15  6.9  17  9.2  76  8.3
Downwardly  mobile 31  21.7  41  18.7  41  22.3  204  22.4
Upwardly mobile 49  34.4  73  33.3  57  31.0  302  33.2
Totals for percentages may not add to 100 because of rounding.
a Statistics are z-scores for continuous variables or proportions for categorical variables.
b p ≤ 0.05 for comparisons between incident and persistent not elevated (reference group) tracking groups.
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r  maintain  their  sPLA2  enzyme  activity  trajectories.  These
ata  align  with  studies  that  have  assessed  the  inﬂuence
f  lifestyle-related  variables  on  tracking  of  other  cardio-
ascular  risk  factors23,24 and  cross-sectional  observations  in
dults  that  suggested  lifestyle  factors  (not  smoking,  healthy
MI,  higher  alcohol  and  protein  intake)  were  associated
ith  lower  lipoprotein-associated  phospholipase  A2  levels,
 family  member  of  sPLA2  purported  to  have  similar  pro-
therosclerotic  actions.27 Our  data  reinforce  these  previous
ndings  by  suggesting  therapeutic  lifestyle  guidelines  pro-
oted  in  primary  and  primordial  prevention  guidelines  for
raditional  risk  factors  have  potential  health  beneﬁts  also
or  sPLA2  enzyme  activity  levels  --  which  may  further  reduce
VD  risk  later  in  life.  One  potential  mechanism  underlying
he  association  of  healthy  improvement  in  fruit  consump-
ion,  smoking,  BMI  with  change  in  sPLA2  levels  may  be  a
eduction  in  the  production  of  proinﬂammatory  cytokines
umour  necrosis  factor-  and  interleukins  that  enhance  syn-
hesis  and  expression  of  sPLA2.28
This  study  had  limitations.  Serum  samples  used  to  assay
PLA2  levels  were  stored  for  up  to  35  years  with  baseline
nd  follow-up  samples  stored  at  different  temperatures.  It
s  not  known  how  stable  sPLA2  levels  are  under  different
torage  temperatures  or  the  rate  of  degradation  over  time.
he  difference  in  mean  values  of  sPLA2  activity  from  18  year
lds  stored  since  1980  compared  with  those  measured  in
4  year  olds  stored  since  2001  (Fig.  1)  is  more  than  might
e  expected  by  a  6-year  age  differential,  which  suggests
egradation  from  longer  storage.  To  mitigate  this  effect,
nd  because  all  samples  from  each  time-point  were  kept
nder  the  same  conditions,  our  analyses  examined  tracking
c
o
ped (reference group) tracking groups or resolution and persistent
sing  ranks  at  both  time-points  rather  than  use  of  absolute
evels.  In  addition,  the  consistent  pattern  in  sPLA2  levels
bserved  across  birth  cohorts  at  both  time-points  (Fig.  1)
uggest  that  those  with  higher  levels  did  not  have  greater
egradation.  As  this  is  the  ﬁrst  study  to  report  sPLA2  enzyme
ctivity  levels  in  a  population-based  sample  of  children,  we
re  unable  to  compare  our  sPLA2  enzyme  activity  levels
ith  levels  in  children  from  similar  studies  analysed  from
resh  samples.  Data  from  the  self-reported  questionnaires
SEP,  smoking,  diet,  physical  activity)  may  lead  to  recall
ias,  where  participants  may  have  failed  to  respond  accu-
ately.  This  would  have  likely  resulted  in  underestimating
he  true  effect,  which  may  explain  some  instances  where
e  observed  non-signiﬁcant  differences  between  groups.
oss  to  follow-up  from  the  original  cohort  is  an  unavoidable
roblem  in  any  study  conducted  over  an  extended  period
f  time.  However,  retention  of  participants  is  high  in  this
ohort  compared  with  similar  studies.29,30 Because  partici-
ants  who  remained  in  the  study  were  more  likely  to  be  older
nd  female,  but  otherwise  similar  in  respect  to  other  base-
ine  variables,30 we  believe  bias  owing  to  differential  loss  to
ollow-up  to  be  limited.  A  further  limitation  is  that  data  on
PLA2  levels  were  only  available  at  two  time-points  and  we
annot  determine  when  changes  in  sPLA2  levels  occurred,
or  identify  those  who  underwent  multiple  changes  during
he  21-year  period.  Finally,  because  the  cohort  is  racially
omogenous,  these  ﬁndings  can  only  be  generalised  to  Cau-
asians  in  Europe.
This  study  had  several  strengths.  Due  to  the  storage
f  samples  since  childhood,  we  were  able  to  provide  the
resented  data  long  before  contemporary  cohorts  could
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examine  similar  aims.  The  large  sample  size,  long  duration  of
follow-up,  with  participants  of  different  social  backgrounds
and  who  are  well  phenotyped  allows  our  ﬁndings  to  be  gener-
alised  at  a  population  level  and  to  infer  long-term  estimates
of  effect.30
Our  ﬁndings  show  that  childhood  elevations  in  sPLA2
levels  associate  with  elevated  sPLA2  levels  in  adulthood.
Further,  our  data  suggest  that  intervention  and  prevention
programmes  that  aim  to  improve  conventional  modiﬁable
risk  factors  for  CVD  by  advocating  for  not  smoking,  higher
fruit  consumption,  and  reduced  excess  adiposity  in  the  time
between  childhood  and  adulthood  might  inﬂuence  whether
individuals  maintain,  develop,  or  resolve  elevated  child
sPLA2  levels.
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